Location · Kansas City, KS
Clinical trials in Kansas City, KS
148 recruiting studies have a site in Kansas City, and 30 of them accept healthy volunteers.
148 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Kansas City, KS + 18 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Generate Biomedicines
- Location
- Kansas City, KS + 21 other US sites
- Eligibility basics
- Ages 12–80
- Recruiting
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
Valencia Technologies Corporation
- Location
- Kansas City, KS + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Kansas City, KS + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Cabaletta Bio
- Location
- Kansas City, KS + 16 other US sites
- Eligibility basics
- Ages 18–70
- Recruiting
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Apreo Health, Inc.
- Location
- Kansas City, KS + 17 other US sites
- Eligibility basics
- Ages 40–84
- RecruitingPhase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Annexon, Inc.
- Location
- Kansas City, KS + 19 other US sites
- Eligibility basics
- Ages 8–85
- RecruitingPhase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi
- Location
- Kansas City, KS + 72 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2/Phase 3
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Cabaletta Bio
- Location
- Kansas City, KS + 9 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
Boehringer Ingelheim
- Location
- Kansas City, KS + 21 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Rein Therapeutics
- Location
- Kansas City, KS + 19 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2/Phase 3
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Cabaletta Bio
- Location
- Kansas City, KS + 29 other US sites
- Eligibility basics
- Ages 6–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB Biopharma SRL
- Location
- Kansas City, KS + 61 other US sites
- Eligibility basics
- Ages 16+
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Sanofi
- Location
- Kansas City, KS + 18 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Boehringer Ingelheim
- Location
- Kansas City, KS + 55 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Gossamer Bio USA, Inc.
- Location
- Kansas City, KS + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca
- Location
- Kansas City, KS + 70 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Kansas City, KS + 80 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
Reprieve Cardiovascular, Inc
- Location
- Kansas City, KS + 33 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Pfizer
- Location
- Kansas City, KS + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Insmed Incorporated
- Location
- Kansas City, KS + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Kansas City, KS + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Sanofi
- Location
- Kansas City, KS + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Insmed Incorporated
- Location
- Kansas City, KS + 10 other US sites
- Eligibility basics
- Ages 18–75